Trials / Completed
CompletedNCT01897116
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I study combining vemurafenib and hydroxychloroquine in the treatment of BRAF V600E+ metastatic melanoma.
Detailed description
This study is testing vemurafenib and hydroxychloroquine (HCQ) in the treatment of metastatic BRAF V600E+ melanoma. Patients will be getting a known active treatment for their disease in combination with HCQ which may help overcome resistance so that responses to vemurafenib are more durable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydroxychloroquine (HCQ) | |
| DRUG | Vemurafenib (VEM) |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2016-07-12
- Completion
- 2016-10-05
- First posted
- 2013-07-11
- Last updated
- 2020-05-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01897116. Inclusion in this directory is not an endorsement.